Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine – November 11, 2024
Source: OpenAlex
Summary
Breakthroughs in medicine offer new hope for major depressive disorder, a condition with an enormous global economic burden. Brexanolone and zuranolone, the first FDA-approved drugs for postpartum depression, signify a critical advancement in maternal mental health. These transformative therapies provide rapid relief for a vulnerable population. Psilocybin also shows promise for treatment-resistant depression, signaling a significant stride in psychiatry and psychology. Such innovations aim to reshape treatment, impacting identity and memory through effective therapy.
Abstract
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our ability to provide rapid-acting, effective treatment that achieves remission. Brexanolone and zuranolone, the first US Food and Drug Administration–approved drugs for postpartum depression, signify a critical advancement in addressing the unmet needs of a vulnerable patient population. Psilocybin shows promise for treatment-resistant depression and for those who have struggled to find relief with existing treatments. This review discusses transformative therapies that represent significant advancements in postpartum depression, major depressive disorder, and treatment-resistant depression.